Profile data is unavailable for this security.
About the company
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development (R&D), current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. Its business divisions include discovery services, R&D centers, development services, and manufacturing services. It serves the pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. It operates multi-modal biologics manufacturing facility.
- Revenue in INR (TTM)34.70bn
- Net income in INR4.92bn
- Incorporated1993
- Employees6.51k
- LocationSyngene International LtdSyngene International Ltd, Biocon Park, SEZ,, Bommasandra IndustrBANGALORE 560099IndiaIND
- Phone+91 8 068918000
- Fax+91 8 068918808
- Websitehttps://www.syngeneintl.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RemeGen Co Ltd | 16.72bn | -19.01bn | 193.67bn | 3.50k | -- | 4.01 | -- | 11.59 | -3.27 | -3.27 | 2.87 | 5.42 | 0.2411 | 0.4413 | 6.06 | 427,581.40 | -27.42 | -18.66 | -35.04 | -23.75 | 77.11 | 81.94 | -113.72 | -102.88 | 1.06 | -31.41 | 0.4737 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
| Peptidream Inc | 31.41bn | 12.29bn | 210.64bn | 603.00 | 17.10 | 6.30 | 15.45 | 6.71 | 167.15 | 167.15 | 427.44 | 453.44 | 0.7217 | 4.49 | 2.97 | 91,906,740.00 | 28.25 | -- | 33.81 | -- | 77.98 | -- | 39.14 | -- | 3.23 | 14.72 | 0.2626 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Dizal Jiangsu Pharmaceutical Co Ltd | 3.53bn | -11.23bn | 217.96bn | 581.00 | -- | 29.91 | -- | 61.78 | -2.29 | -2.29 | 0.7174 | 1.47 | 0.1742 | 0.4174 | 4.62 | 507,467.80 | -60.62 | -46.02 | -81.84 | -52.99 | 96.75 | 57.53 | -347.91 | -2,081.54 | 1.81 | -- | 0.5253 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Sinocelltech Group Ltd | 28.53bn | -1.59bn | 220.42bn | 2.33k | -- | -- | -- | 7.73 | -0.2974 | -0.2974 | 5.35 | -1.03 | 0.818 | 0.4037 | 5.81 | 1,021,836.00 | -4.55 | -40.17 | -13.68 | -74.63 | 96.26 | 95.42 | -5.56 | -108.20 | 0.5057 | 4.62 | 1.19 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 34.06bn | 13.07bn | 297.15bn | 1.04k | 22.74 | 5.50 | -- | 8.72 | 2.43 | 2.43 | 6.32 | 10.03 | 0.6579 | 3.28 | 10.58 | 2,726,042.00 | 25.24 | 0.6405 | 27.43 | 0.6933 | 94.47 | 96.42 | 38.37 | 2.54 | 7.88 | -- | 0.0003 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Genscript Biotech Corp | 84.80bn | -14.87bn | 334.30bn | 7.28k | -- | 3.27 | -- | 3.94 | -0.6495 | -0.6495 | 3.71 | 4.44 | 0.3006 | 9.15 | 7.99 | 1,130,268.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Syngene International Ltd | 34.70bn | 4.92bn | 348.42bn | 6.51k | 71.00 | -- | 37.75 | 10.04 | 12.24 | 12.24 | 86.29 | -- | -- | -- | -- | 5,330,569.00 | -- | 8.62 | -- | 11.43 | 72.89 | 71.13 | 14.19 | 16.22 | -- | 7.57 | -- | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Telix Pharmaceuticals Ltd | 36.65bn | 2.79bn | 389.21bn | 234.00 | 136.87 | 16.95 | 121.52 | 10.62 | 0.1497 | 0.1497 | 1.96 | 1.21 | 1.22 | 11.36 | 8.61 | -- | 9.31 | -29.08 | 15.01 | -40.27 | 61.80 | 61.64 | 7.62 | -37.14 | 0.8687 | -- | 0.052 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| Biocon Ltd | 147.66bn | 15.81bn | 407.07bn | 3.68k | 25.75 | -- | 11.22 | 2.76 | 13.20 | 13.20 | 123.37 | -- | -- | -- | -- | 40,114,100.00 | -- | 3.20 | -- | 4.48 | 67.01 | 62.04 | 13.62 | 9.37 | -- | 1.54 | -- | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 22.47bn | -2.79bn | 521.55bn | 1.54k | -- | 13.58 | -- | 23.21 | -1.14 | -1.14 | 9.39 | 15.94 | 0.5869 | 9.46 | 167.74 | 1,468,051.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| ICICI Prudential Asset Management Co. Ltd.as of 31 Jul 2024 | 26.31m | 6.54% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Jul 2024 | 8.05m | 2.00% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Jul 2024 | 7.90m | 1.96% |
| Norges Bank Investment Managementas of 30 Jun 2023 | 7.03m | 1.75% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Jul 2024 | 6.34m | 1.57% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 6.14m | 1.52% |
| First Sentier Investors (Australia) IM Ltd.as of 31 Mar 2024 | 6.08m | 1.51% |
| Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 30 Jun 2023 | 4.01m | 1.00% |
| PGIM India Asset Management Pvt Ltd.as of 31 Jul 2024 | 3.25m | 0.81% |
| JPMorgan Asset Management (Asia Pacific) Ltd.as of 30 Jun 2024 | 2.77m | 0.69% |
